key: cord-0818060-9dnkm07a authors: Molina, María; Burgos, Elena; Cacho, Judit; Juega, Javier; Cañas, Laura; Taco, Omar; Perezpaya, Ines; Jou, Marina Urrutia; Martinez, Javier Paul; Graterol, Fredzzia; Lauzurica, Ricardo title: Routine biomarkers for the severity of COVID-19 pneumonia may present differently in kidney transplant recipients date: 2021-08-14 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.08.020 sha: 8b7b3d0eb1d13a6c7728b046b2b8106c53a80680 doc_id: 818060 cord_uid: 9dnkm07a Background The treatment of coronavirus disease (COVID-19) is based on the patient's clinical status and levels of inflammatory biomarkers. The comparative activity of these biomarkers in KT patients with COVID-19 pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non-SARS-CoV-2 aetiologies is unknown. Aim To compare the clinical presentation and inflammatory parameters at admission of KT patients with COVID-19 pneumonia and those with non-COVID-19 pneumonia over the same period. Methods Biomarkers were measured and compared between KT patients with COVID-19 pneumonia (n=57) and non-COVID-19 pneumonia (n=20) from March 2020 to March 2021. Results Both groups showed comparable demographics. The COVID-19 KT patients had fewer neutrophils (6,824 ± 5,000 vs. 8,969 ± 4,206, p = 0.09) than the non-COVID group, although there was no significant difference in the lymphocyte count. Non-COVID-19 pneumonia was associated with a higher d-dimer (921 [495-1,680] vs. 2,215 [879-3,934], p = 0.09) and IL-6 (35 [20-128] vs 222 [38-500], p = 0.006) levels. The ferritin level was higher in the COVID-19 group (809 [442-1,330] vs. 377 [276-885], p = 0.008). In multivariable analysis only d-dimer [HR:1 (1-1.002), p=0.02] and ferritin [HR:1 (0.9-0.9), p=0.02] rise the statistic signification. Conclusions COVID-19 pneumonia in KT recipients shows a different presentation of inflammatory biomarkers than other non-COVID pneumonias. It could be usefully to identify KT patients with COVID-19.More detailed studies are necessary to understand the presentation of biomarkers in KT with COVID-19. The pathogenesis of coronavirus disease (COVID-19) includes two different aspects: the tissue damage induced by the virus and the indirect effects caused by an amplified immune response and inflammation mediated by a cytokine storm. This second part is associated with the elevation of some inflammatory parameters such as ferritin, D-dimer, C-reactive protein (CRP) as well as proinflammatory cytokines, such as interleukin (IL)-6, in the general population (1, 2) . These parameters have been used as early and severity markers of COVID-19. In addition, treatment with drugs such as tocilizumab, an IL-6-receptor blocker, is based on clinical progression and the measurement of these inflammatory markers in the general population. The same management protocol has been applied to KT patients. Unfortunately, some of these molecules have not been routinely measured after non-COVID-19 infection in KT patients. Thus, their comparative values in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non-SARS-CoV-2 pneumonias are unknown. Therefore, extrapolation of the same behaviour or cut-off point as that of the immunocompetent population for starting treatment in such patients is debatable(3). This study describes the clinical presentation and inflammatory parameters at admission in a cohort of KT patients with COVID-19 pneumonia and non-COVID-19 pneumonia over the same period. In this retrospective series of cases with non-aleatory randomisation, we included all consecutive KT patients who presented with pneumoniae, and underwent at least two determinations of polymerase chain reaction (PCR) assay with nasal and/or pharyngeal swab specimens for SARS-CoV-2 between March 2020 and March 2021 at the Hospital Germans Trias i Pujol. PCR tests for SARS-CoV-2 are considered the gold standard for acute infection, and the patients were classified as COVID-19positive or COVID-19-negative according to the PCR results. The demographic, clinical, laboratory, and radiological variables were collected retrospectively from the patients' medical records. All patients were followed up until death or discharge. This study was approved by the ethics committee of the hospital. Quantitative data were expressed as the mean (standard deviation) and median with [interquartile range (IQR)], while qualitative variables were expressed as absolute and relative frequencies. The quantitative and qualitative variables were compared using the non-parametric Mann-Whitney Utest and chi-squared test, respectively. A p-value < 0.05 was considered statistically significant. Uni and multivariable logistic regression was made. This study included 77 KT patients with pneumonia and tested them for SARS-CoV-2 using PCR from March 2020 to March 2021, of which 57 tested positive for COVID-19. The patient characteristics and clinical presentation are shown in Table 1 . There were no differences in the baseline characteristics of the two groups, except that the COVID-19 group received a higher percentage of angiotensinconverting enzyme inhibitors or angiotensin receptor blockers (p = 0.05), and therefore showed lower proteinuria. There were no differences in immunosuppression regimens or renal function. The first PCR test confirmed COVID-19 in 53 of the 57 positive cases, since a negative test was initially obtained in four cases that tested positive after 72 hours. Among the 20 non-COVID-19 patients, the PCR test was performed twice in 10 patients and thrice o more time in 10 patients. Two patients tested positive for pneumococcal antigens in urine, one patient showed Enterococcus faecium in the bronchoalveolar lavage (BAL) fluid, and another patient showed PCR-positive findings in the influenza virus test using nasopharyngeal swabs. Table 2 shows the biomarker findings in all patients at admission. Lymphocyte count < 1,200/L were observed in 78% (60) of the patients. The D-dimer level was higher than 500 g/mL in 61 patients (79%), while the IL-6 level was greater than 6.4 pg/mL (normal range) in all of the patients. Table 2 shows the distribution of biomarkers in the COVID-19 and non-COVID-19 groups. In multivariable analysis only D-dimer and ferritin rise the statistic signification (Table 2) . In terms of mortality, 17 of the 57 (29.8%) COVID-19 patients and 1 (5%) non-COVID-19 patient died (p = 0.03). Admission at an intensive care unit and mechanical intubation were required for 19.3% of the SARS-CoV-2 infections vs. 0% of pneumonias attributable to other aetiologies (p = 0.06). However, the proportions of patients received high-flux cannulas and non-invasive mechanical ventilation were higher in COVID-19 group (32.1% vs. 5%, p = 0.01 and 24.5% vs. 0%, p = 0.01, respectively). SARS-CoV-2 infection causes an overwhelming inflammatory reaction with synthesis of inflammatory markers (e.g., CRP, ferritin, and D-dimer) and pro-inflammatory cytokines (e.g., IL-6, TNF, and IL-8)(1, 2). We found that COVID-19 patients had fewer neutrophils than the non-COVID-19 group, although there was no difference in the lymphocyte count. Non-COVID-19 pneumonia was associated with higher RDW values and D-dimer and IL-6 levels than positive SARS-CoV-2 infection. In contrast, the ferritin level was higher in the COVID-19 pneumonia group. The other biomarkers showed no intergroup differences. These biomarkers have not been previously used for the evaluation of the outcome of COVID-19 infection in immunosuppressed patients, and some studies suggested that they may not necessarily work in renal transplant patients in the same way as they do in the general population(3). However, the levels of these molecules are not routinely measured in KT patients presenting with an infection, and the levels of pro-inflammatory biomarkers could be increased by infectious agents other than SARS-CoV-2 as well(1). The immunosuppressive therapy in both groups was similar, and the biomarker data for KT patients with COVID-19 in our study (Table 3) Lymphocytopenia is considered one of the most remarkable markers of COVID-19 and has been proposed as a criterion of diagnosis(1). However, lymphopenia is not specific and has been associated with respiratory infections caused by other viruses in KT patients(4). We did not find any differences in the number of lymphocytes between COVID-19 and non-COVID-19 pneumonia. In immunosuppressed patients who receive drugs with haematological toxicity and experience infections by opportunistic pathogens, lymphopenia cannot be a good marker of SARS-CoV-2 infection. Neutrophil count and NLR are reported to be increased in the general population with COVID-19 (1, 2) . In our study, the neutrophils and NLR were higher in non-COVID-19 patients, but in the multivariable analysis they were not statistically different. On the other hand, RDW was higher in the non-COVID-19 group. In non-SARS-CoV-2 pneumonia, a higher RDW has been related to mortality (4) . Nevertheless, the role of RDW in COVID-19 is unknown. Events such as infections or rejection activate the coagulation cascades and increase the D-dimer levels in KT. The higher D-dimer levels in non-COVID patients in the present study, even after excluding pulmonary oedema or thromboembolism, was a surprising finding. However, an explanation for this finding goes beyond the scope of our study. Nevertheless, we could not find studies that quantified the D-dimer levels in KT patients with infection, and the existing literature (1, 6) . Thus, different triggers could influence the concentration of this interleukin (6) . In our study, all patients showed increased levels of IL-6, but the elevation was higher in patients with non-COVID-19 pneumonia. Considering the non-specific role of IL-6, recent clinical trials with tocilizumab, an IL-6 receptor inhibitor, did not show a benefit in the general population with COVID-19. In general population, the IL-6 level in patients with COVID-19 was lower than that in patients with sepsis and other acute respiratory distress syndromes unrelated to COVID-19 (5). Although ferritin levels are known to increase in pneumonia associated with other infections in KT patients, the ferritin levels associated with SARS-CoV-2 infection in the present study were greater than those associated with non-COVID pathogens. A metanalysis in the general population yielded similar results as in our study. The ferritin level was highly elevated in patients with COVID-19 (5). We performed microbiological diagnosis in only four patients with non-COVID pneumonia. We recollected blood cultures from all patients. Some studies have proven that blood cultures have a suboptimal sensitivity . In contrast, BAL is an established method for detecting pulmonary infectious (7) . However, we encountered limitations in performing diagnostic tests such as BAL and other tests because the hospital resources were focused on COVID-19 patients during the pandemic. The most novel aspect of our study was the measurement of the same inflammatory parameters in the patients with COVID-19 pneumonia and non-COVID-19 pneumonia at the moment of admission. We found one study that employed a similar methodology. Arenas compared haemodialysis and KT patients with confirmed and suspected COVID-19 at a Spanish hospital. In their non-COVID KT group, only one patient had pneumonia, and the laboratory data of this patient were not available (8) . This study had several limitations since it was a descriptive, single-centre study with a small sample size. The control group was extremely heterogeneous, and microbiological diagnoses were not possible in many cases. However, this study questions the specificity of biomarkers in pneumonia caused by COVID-19, and the topic has not been described previously. Nevertheless, we performed biomarker assessments only once in the cohort of patients with SARS-CoV-2 infection, and the measurements were performed at different points of infection. Thus, more measurements will be required to determine the kinetics of the biomarkers. In conclusion, COVID-19 infection in KT patients presents with a distinct inflammatory pattern, namely lower neutrophil counts and D-dimer and IL-6 levels but higher ferritin levels than those observed in non-COVID-19 pneumonia. However, the small sample size of our study may have limited the detection of other differences. To increase the knowledge about biochemical presentation of SARS-CoV-2 infection in KT patients could be helpful to differentiate COVID from other diseases. An explanation of the enteropathogenesis of the differences in the infection biomarkers was also beyond the scope of this study. Larger studies with KT patients, ideally using logistic regression and ROC curve methods, are required for a more robust evaluation of the ability of these inflammation biomarkers to discriminate the occurrence of COVID-19 pneumonia from pneumonia caused by other aetiologies. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States Association Between Red Blood Cell Distribution Width and Prognosis of Renal Transplant Recipients with Early-Onset Pneumonia Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Pneumonia after kidney transplant: incidence, risk factors, and mortality Clinical Profiles in Renal Patients with COVID-19 ALT: alanine aminotransferase; CK: creatine kinase; CI: confidence intervale; COVID-19: coronavirus disease 2019; CRP: c-reactive protein; HR: hazard ratio; IL-6: interleukine-6; LDH: lactate dehydrogenase; NLR: neutrophil-to-lymphocyte rate; MLR: Monocytes-to-lymphocyte rate; PLR: Platelet-to-lymphocyte ratio Tables.